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Background-—The Valve Academic Research Consortium (VARC) has proposed a standardized deﬁnition of bleeding in patients
undergoing transcatheter aortic valve interventions (TAVI). The VARC bleeding deﬁnition has not been validated or compared to
other established bleeding deﬁnitions so far. Thus, we aimed to investigate the impact of bleeding and compare the predictivity of
VARC bleeding events with established bleeding deﬁnitions.
Methods and Results-—Between August 2007 and April 2012, 489 consecutive patients with severe aortic stenosis were included
into the Bern-TAVI-Registry. Every bleeding complication was adjudicated according to the deﬁnitions of VARC, BARC, TIMI, and
GUSTO. Periprocedural blood loss was added to the deﬁnition of VARC, providing a modiﬁed VARC deﬁnition. A total of 152
bleeding events were observed during the index hospitalization. Bleeding severity according to VARC was associated with a gradual
increase in mortality, which was comparable to the BARC, TIMI, GUSTO, and the modiﬁed VARC classiﬁcations. The predictive
precision of a multivariable model for mortality at 30 days was signiﬁcantly improved by adding the most serious bleeding of VARC
(area under the curve [AUC], 0.773; 95% conﬁdence interval [CI], 0.706 to 0.839), BARC (AUC, 0.776; 95% CI, 0.694 to 0.857), TIMI
(AUC, 0.768; 95% CI, 0.692 to 0.844), and GUSTO (AUC, 0.791; 95% CI, 0.714 to 0.869), with the modiﬁed VARC deﬁnition
resulting in the best predictivity (AUC, 0.814; 95% CI, 0.759 to 0.870).
Conclusions-—The VARC bleeding deﬁnition offers a severity stratiﬁcation that is associated with a gradual increase in mortality
and prognostic information comparable to established bleeding deﬁnitions. Adding the information of periprocedural blood loss to
VARC may increase the sensitivity and the predictive power of this classiﬁcation. ( J Am Heart Assoc. 2015;4:e002135 doi:
10.1161/JAHA.115.002135)
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T ranscatheter aortic valve implantation (TAVI) hasbecome an established treatment alternative to conven-
tional, surgical aortic valve replacement (SAVR) in high-risk
patients with symptomatic, severe aortic stenosis and is
considered the treatment of choice for inoperable patients.1–4
Owing to the substantial differences in invasiveness between
TAVI and SAVR, major bleeding complications and packed red
blood cell (PRBC) transfusions have been shown to be 2 to 3
times less frequent among patients undergoing TAVI, com-
pared to those undergoing SAVR, in the PARTNER trial.5
However, periprocedural bleeding complications post-TAVI
remain common, incur a signiﬁcant increase in healthcare
costs,6 and are associated with adverse clinical outcomes
during long-term follow-up.5,7,8
Although early TAVI reports varied considerably in terms of
frequency and type of complications owing to the lack of
standardized endpoint deﬁnitions,9–11 this was successfully
addressed by the Valve Academic Research Consortium
(VARC) in 2011.12 The ﬁrst VARC consensus document aimed
to harmonize endpoint deﬁnitions in TAVI trials and registries
and provide guidance for uniform and standardized reporting
of clinical outcomes. Subsequent to the implementation of
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these ﬁrst set of guidelines, recommendations were revisited
and updated in view of initial experiences and to address the
future needs of clinical trials culminating in the VARC-2
consensus document.13 Similar to the previous version,
VARC-2 categorizes bleeding complications according to the
severity in minor, major, and in life-threatening type and
acknowledges the previously established recommendation of
the BleedingAcademic ResearchConsortium (BARC).14 VARC-2
endpoint deﬁnitions are based on expert consensus and have
not been validated in a real-world TAVI patient population to
date. Thus, the aim of the present study was to evaluate the
impact of bleeding according to the VARC-2 endpoint deﬁnition
on clinical outcomes and compare the predictive power of
VARC-2 bleeding events with other established bleeding
deﬁnitions within the Bern TAVI cohort.
Methods
Patient Population
Between August 2007 and April 2012, 489 consecutive
patients with symptomatic severe aortic stenosis were
included into a single center registry (Bern TAVI Registry).
All patients underwent TAVI with the self-expanding Medtronic
CoreValve (Medtronic, Minneapolis, MN), the balloon-expand-
able Edwards Sapien THV or XT prosthesis (Edwards
Lifesciences, Irvine, CA) using the transfemoral, transapical,
or subclavian access route, and the self-expanding Symetis
Acurate TA prosthesis (Symetis SA, Ecublens VD, Switzerland)
using the transapical access route.11 Patients underwent TAVI
after consensus reached within the local Heart Team
consisting of invasive cardiologists and cardiac surgeon. With
the institutional policy to perform TAVI using the least invasive
strategy, device and access route selection was based on the
individual anatomical characteristics after a sophisticated
imaging evaluation using transthoracic and transesophageal
echocardiography, multislice computed tomography and
coronary angiography. The study complied with the declaration
of Helsinki, and the registry was approved by the local ethics
committee. All patients provided written informed consent
to participate in the registry with prospective follow-up
assessment.
Procedure
The procedure was performed according to local practice and
expertise, as previously described.15 Periprocedural treatment
consisted of unfractionated heparin (70 to 100 U/kg) to
maintain an activated clotting time of more than 250 sec-
onds, aspirin 100 mg qd, and clopidogrel (300 mg loading
1 day before the procedure followed by 75 mg qd for 3 to
6 months). For patients with an indication for oral anticoag-
ulation, a vitamin K antagonist was combined with either low-
dose acetylsalicylic acid or clopidogrel and according to the
individual bleeding risk. Heparin administration was not
routinely reversed by using protamine sulfate at the end of
a successful procedure. After the procedure, patients were
either transferred to an intensive care unit or a coronary care
unit and monitored for at least 48 hours after the intervention
for rhythm disturbances, neurological deﬁcits, access-related
and bleeding complications, or other serious adverse events.
Blood sample and hemoglobin level assessment was per-
formed at baseline, directly after the intervention, and was
followed by a routine assessment on a daily basis among
patients without signs of bleeding. Patients with bleeding
complications had a hemoglobin assessment every 6 hours
until stabilization as part of the routine institutional practice.
Data Collection and Endpoint Assessment
All patients were closely monitored during the index hospi-
talization and during follow-up. After discharge, adverse
events were assessed through active follow-up at 30 days
and 12 months by either clinical in-hospital visits or a
standardized telephone interview. In case of readmission to
the hospital or other medical institutions, external medical
records, discharge letters, and interventional reports including
the full hematological report were systematically collected.
Baseline clinical and procedural characteristics as well as
follow-up data were entered into a dedicated Web-based
database, held at an academic clinical trials unit (Clinical
Trials Unit Bern, Bern University Hospital, Bern, Switzerland)
responsible for central data audits and maintenance of the
database.
All suspected events were presented to a dedicated clinical
event committee consisting of cardiologists and cardiac
surgeons, and serious adverse events were adjudicated
according to the standardized endpoint deﬁnitions proposed
by the Valve Academic Research Consortium.13
Deﬁnitions
For the purpose of this study, every single bleeding compli-
cation during the index hospitalization was reviewed by 2
investigators (S.S. and G.G.S.) according to the patient charts,
available reports, and the full hematological report. After
reevaluating the severity of the complications, all events were
reclassiﬁed and adjudicated according to the bleeding deﬁ-
nitions proposed by the Valve Academic Research Consortium
(VARC-213), the Bleeding Academic Research Consortium
(BARC14), the Thrombolysis in Myocardial Infarction investi-
gators (TIMI16), and the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Arteries
investigators (GUSTO17). Both investigators (S.S. and G.G.S.)
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needed to agree on bleeding severity classiﬁcation according
to the predeﬁned bleeding deﬁnitions, and in case of
disagreement, adjudication was performed and disagreement
resolved by a third investigator (S.W.).
For every single case of bleeding, the full source
documentation was available and additional information for
the localization of bleeding, several imaging tests, hemoglobin
level, platelet count, and PRBC transfusion was collected.
Furthermore, the hematological laboratory reports preceding
TAVI and during the index hospitalization, as well as PRBC
transfusions, were evaluated in all patients to identify peri-
and postprocedural blood loss according to the deﬁnitions of
VARC 2, BARC, TIMI, and GUSTO. Periprocedural blood loss
was calculated from the baseline and the ﬁrst blood sample
assessment after the procedure, and the drop in hemoglobin
was added to the deﬁnition criteria of VARC-2 creating the
modiﬁed VARC deﬁnition of bleeding.
Statistical Analysis
All statistical analyses were performed by a statistician at
an academic clinical trials unit (D.H. and P.J., Clinical Trials
Unit Bern, Bern University Hospital, Bern, Switzerland) using
Stata software (version 12.1; StataCorp LP, College Station,
TX). Categorical variables were summarized as counts and
frequencies (%) and were compared by using the chi-square
test (or Fisher’s test for 2 group comparisons), whereas
continuous variables were presented as meansSD and
compared using ANOVA. A description of the location and
the severity of bleeding events adjudicated according to the
updated VARC-2 deﬁnition was presented as counts and
frequencies (%). The ﬁrst bleeding event during the index
hospitalization after TAVI was described using the bleeding
deﬁnition of VARC-2, BARC, TIMI, and GUSTO. For every
deﬁnition, mortality rates from patients with a bleeding
event adjudicated according to the most severe bleeding
category were compared with rates from patients that had
less severe or no bleeding complication. Incidence rates as
well as relative risks (RRs) with 95% conﬁdence intervals
(95% CIs) were calculated using Poisson regression. Land-
mark analysis with a prespeciﬁed landmark at 30 days was
performed to evaluate early and late RR of mortality
associated with bleeding. Cox regression was used to
evaluate the hazard ratio (HR) with 95% CI for death at
30 days, between 30 days and 1 year, and up to 1-year
follow-up. Uni- and multivariate models were constructed to
derive adjusted HRs with 95% CI for mortality at 30 days,
including the baseline confounders age, sex, body mass
index, previous stroke, chronic obstructive pulmonary
disease, and atrial ﬁbrillation.
Sensitivity, speciﬁcity, and accuracy with respect to 30-day
mortality were calculated for the different bleeding deﬁnitions
and compared with the McNemar tests, taking VARC2 life-
threatening bleeding complications as a reference. Likelihood
ratio tests were performed for the different multivariate
models, including bleeding events, and compared to a
multivariate model with the baseline confounders age, sex,
body mass index, previous stroke, chronic obstructive
pulmonary disease, and atrial ﬁbrillation. The discriminatory
power for mortality at 30 days of different multivariable
models with and without bleeding complications according to
the bleeding deﬁnitions of VARC-2, BARC, TIMI, and GUSTO
were assessed using receiver operating characteristic (ROC)
curves. Multivariable models were used to construct adjusted
ROC curves and compute areas under the curve (AUCs).
Bootstrap analysis (200 samples) was used to calculate CIs of
AUC. A 2-sided P value less than 0.05 was considered to
indicated statistical signiﬁcance.
Results
Between August 2007 and April 2012, 489 consecutive
patients underwent TAVI using the femoral (79%), transapical
(20%), and subclavian access route (1%) for treatment of
symptomatic, severe aortic valve stenosis. Overall, a total of
130 patients (26.6%) had a bleeding complication during the
index hospitalization. Scheduled follow-up with prospective
endpoint assessment was complete for all patients at 30 days
and 12 months after TAVI (100%).
Baseline clinical characteristics are summarized in
Table 1. At baseline, patients with in-hospital bleeding
complication were older (no bleeding vs in-hospital bleeding
81.96.1 vs 83.94.5; P=0.001) and more frequently had
previous bleeding events in their past medical history (10% vs
24%; P<0.001). Furthermore, they less frequently had previ-
ous coronary artery bypass grafting (18% vs 8%; P=0.007) and
presented with smaller mean aortic valve area (0.610.21 vs
0.560.23; P=0.019), compared to patients without bleeding
complication, during the index hospitalization. Procedural
duration (no bleeding vs in-hospital bleeding 64.931 vs
74.451 minutes; P=0.014) and overall in-hospital length of
stay (7.34 vs 8.87; P=0.004) were longer for patients with
in-hospital bleeding complication, whereas access route,
valve type, and other procedural speciﬁcations and in-hospital
characteristics were similar between groups as displayed in
Table 2.
Bleeding Complications and Periprocedural Blood
Loss
A total of 152 bleeding events were observed in 130 patients
post-TAVI during the index hospitalization. The majority of
bleeding complications were considered access-site related or
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have been classiﬁed as vascular events (66.4%) and were
adjudicated as life-threatening in 37.6%, major in 43.6%, and
minor complication in 18.8% of events according to the VARC-2
deﬁnition. A detailed list of the location and the severity
assessment of bleeding events is provided in Table 3.
Periprocedural blood loss without signs of overt bleeding
Table 1. Baseline Clinical Characteristics
All Patients
N=489
NO Bleeding*
N=359
Overt Bleeding
N=130 P Value
Age, y 82.55.7 81.96.1 83.94.5 0.001
Female sex, n (%) 269 (55) 192 (53) 77 (59) 0.30
Body mass index, kg/m2 26.24.9 26.24.9 26.14.9 0.80
Diabetes mellitus, n (%) 131 (27) 95 (26) 36 (28) 0.82
Hypercholesterolemia, n (%) 304 (62) 229 (64) 75 (58) 0.21
Hypertension, n (%) 400 (82) 295 (82) 105 (81) 0.79
Past medical history
Previous bleeding event, n (%) 66 (13) 35 (10) 31 (24) <0.001
Previous myocardial infarction, n (%) 77 (16) 58 (16) 19 (15) 0.78
Previous coronary artery bypass graft, n (%) 77 (16) 66 (18) 11 (8) 0.007
Previous percutaneous coronary intervention, n (%) 123 (25) 94 (26) 29 (22) 0.41
Peripheral vascular disease, n (%) 106 (22) 85 (24) 21 (16) 0.082
Chronic obstructive pulmonary disease, n (%) 88 (18) 66 (18) 22 (17) 0.79
Clinical features
Anemia†, n (%) 276 (56) 212 (59) 64 (49) 0.063
Renal failure (GFR <60 mL/min per 1.73 m2) 329 (67%) 235 (65%) 94 (72%) 0.16
Coronary artery disease, n (%) 295 (60) 219 (61) 76 (58) 0.68
Atrial fibrillation, n (%) 139 (28) 103 (29) 36 (28) 0.91
Left ventricular ejection fraction, % 52.415.0 52.2415.14 52.714.5 0.77
Aortic valve area, cm2 0.600.2 0.610.2 0.560.2 0.019
Mean transaortic gradient, mm Hg 43.417.3 42.617.0 45.517.8 0.11
Laboratory values
Hemoglobin, g/L 120.915.9 120.915.3 120.917.5 0.98
Platelet count, 9109/L 218.076.6 216.878.3 221.272.1 0.57
Risk assessment
Logistic EuroScore, % 23.413.8 23.413.9 23.613.6 0.88
EuroScore II, % 8.58.1 8.68.7 8.26.5 0.62
STS Score, % 6.85.2 6.75.2 7.05.1 0.62
Antithrombotic therapy
Aspirin, n (%) 303 (62) 223 (63) 80 (62) 0.83
Clopidogrel, n (%) 98 (20) 73 (21) 25 (19) 0.80
Oral anticoagulation, n (%) 131 (27) 102 (29) 29 (22) 0.17
Aspirin and clopidogrel, n (%) 78 (16) 60 (17) 18 (14) 0.49
Oral anticoagulation and aspirin, n (%) 26 (5) 20 (6) 6 (5) 0.82
Oral anticoagulation and clopidogrel, n (%) 14 (3) 10 (3) 4 (3) 1.00
Oral anticoagulation, aspirin and clopidogrel, n (%) 7 (1) 6 (2) 1 (1) 0.68
Depicted are meanSD with P values from ANOVAs, or counts (%) with P values from chi-square tests. GFR indicates glomerular ﬁltration rate; STS, Society of Thoracic Surgeons.
*The “no bleeding” group includes 120 patients who have had periprocedural blood loss.
†
Anemia was deﬁned as hemoglobin less than 120 g/L for women and less than 130 g/L for men.
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was observed in 120 patients and has been classiﬁed as life-
threatening in 20.0%, major in 59.2%, and minor in 20.8% of
events according to VARC2 (Table 3).
Bleeding Complications and Mortality
Among 489 patients undergoing TAVI, a total of 16 patients
died during the index hospitalization before hospital discharge
(3.3%), 28 deaths were observed within the ﬁrst 30 days
(5.7%), and 82 deaths within 12 months of follow-up (16.8%).
All-cause death during the index hospitalization, at 30 days
and 12 months mortality amounted to 0.4%, 2.1%, and 14.2%
among patients with neither overt bleeding nor periprocedural
blood loss, was 1.8%, 10.8%, and 23.4% among patients with
bleeding complications, and amounted to 1.0%, 7.5%, and
25.2% among patients with periprocedural blood loss,
respectively. A gradual increase in mortality was observed
according to the severity of bleeding complication for VARC-2,
BARC, TIMI, GUSTO, and the modiﬁed VARC deﬁnition
(Table 4). At 30 days, VARC-2 life-threatening, BARC ≥3,
and TIMI major bleeding were associated with an approxi-
mately 4-fold increased risk (HR, 4.3; 95% CI, 2.0 to 9.4; HR,
3.7; 95% CI, 1.8 to 7.7; HR, 4.0;, 95% CI, 1.8 to 8.9), compared
to patients with no or less-severe bleeding, whereas GUSTO
severe or life-threatening and the modiﬁed life-threatening
VARC classiﬁcation were associated with a 12- and 6-fold
Table 2. Procedural Characteristics
All Patients
N=489
No Bleeding*
N=359
Overt Bleeding
N=130 P Value
Procedural characteristics
Procedure time, min 67.437.4 64.930.9 74.451.1 0.014
Length of hospital stay, days 7.75.3 7.34.4 8.87.1 0.004
General anesthesia, n (%) 194 (40) 143 (40) 51 (39) 0.92
New onset of atrial fibrillation, n (%) 36 (7) 24 (7) 12 (9) 0.33
Access route 0.13
Femoral, n (%) 386 (79) 276 (77) 110 (85)
Apical, n (%) 97 (20) 79 (22) 18 (14)
Subclavian, n (%) 6 (1) 4 (1) 2 (2)
Valve type 0.51
Medtronic CoreValve, n (%) 267 (55) 198 (55) 69 (53)
Edwards Sapien valve, n (%) 219 (45) 158 (44) 61 (47)
Symetis ACURATE TA, n (%) 3 (1) 3 (1) 0 (0)
Revascularization
Concomitant PCI, n (%) 80 (16) 54 (15) 26 (20) 0.21
Staged PCI, n (%) 50 (10) 33 (9) 17 (13) 0.24
Procedural specifications
Post-TAVI—need for permanent pacemaker, n (%) 122 (25) 82 (23) 40 (31) 0.077
Post-TAVI—aortic regurgitation ≥2 56 (12%) 41 (12%) 15 (12%) 1.00
Valve in series, n (%) 9 (2) 7 (2) 2 (2) 1.00
Antithrombotic therapy after TAVI (at discharge)
Aspirin, n (%) 399 (85) 300 (86) 99 (83) 0.46
Clopidogrel, n (%) 363 (78) 273 (78) 90 (76) 0.61
Oral anticoagulation, n (%) 145 (31) 110 (32) 35 (29) 0.73
Aspirin and clopidogrel, n (%) 320 (68) 241 (69) 79 (66) 0.65
Oral anticoagulation and aspirin, n (%) 87 (19) 68 (19) 19 (16) 0.42
Oral anticoagulation and clopidogrel, n (%) 54 (12) 42 (12) 12 (10) 0.62
Oral anticoagulation, aspirin and clopidogrel, n (%) 20 (4) 16 (5) 4 (3) 0.79
Depicted are meanSD or counts (%). PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.
*The “no bleeding” group includes 120 patients with periprocedural blood loss.
DOI: 10.1161/JAHA.115.002135 Journal of the American Heart Association 5
VARC Bleeding Complications Stortecky et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at UNIVERSITAETSSPITAL-BIBLIOTHEK BERN on November 5, 2015http://jaha.ahajournals.org/Downloaded from 
increased risk for mortality, respectively (HR, 11.5; 95% CI,
4.9 to 27.0; HR, 6.1; 95% CI, 2.9 to 12.9). Landmark analysis
demonstrated an increased risk of mortality only during the
ﬁrst 30 days after the intervention for VARC-2, BARC, TIMI,
and GUSTO deﬁnitions, whereas the risk of mortality contin-
ued to increase up to 12 months of follow-up with the
modiﬁed VARC bleeding deﬁnition without reaching statistical
signiﬁcance (Table 5 and Figure 1).
Predictors of Mortality and Predictive Power of
Bleeding Deﬁnitions
The predictive precision of bleeding according to the deﬁni-
tions of VARC-2, BARC, TIMI, GUSTO, and the modiﬁed VARC
deﬁnition was assessed by calculating the c-statistics for
multivariable models by stepwise, including the bleeding
events of each bleeding deﬁnition (Table 6). Bleeding, as well
as periprocedural blood loss, was associated with a marked
increase of mortality, which was independent of all baseline
confounders.
The predictive accuracy of VARC-2, BARC, TIMI, GUSTO,
and the modiﬁed VARC bleeding deﬁnition is presented in
Table 7 and Figure 2. Whereas the sensitivity for 30 day
mortality was similar between bleeding deﬁnitions, signiﬁcant
differences were observed for BARC, GUSTO, and the
modiﬁed VARC deﬁnition, compared to the life-threatening
bleeding complication of VARC-2. A nonsigniﬁcant increase in
sensitivity and a signiﬁcant decrease in speciﬁcity were
observed by adding periprocedural blood loss to the VARC-2
deﬁnition of life-threatening bleeding without losing the
accuracy of the deﬁnition.
Discussion
The present study investigating the predictive power of in-
hospital bleeding complications according to the updated
VARC-2 endpoint deﬁnitions on clinical outcomes has the
following main ﬁndings:
1. Bleeding, according to the endpoint deﬁnition of VARC-2,
is independently associated with an increased risk of
mortality at 30 days and 12 months of follow-up post-
TAVI. Moreover, there is a gradual increase in impaired
clinical outcome post-TAVI with increasing severity of
bleeding as deﬁned by VARC-2.
2. The predictive power of the VARC-2 bleeding deﬁnition is
comparable to previously established and validated
bleeding deﬁnitions (BARC, TIMI, and GUSTO).
3. Periprocedural blood loss and a relevant drop of
hemoglobin during TAVI is independently associated with
an increased risk of mortality after 30 days and
12 months.
4. Adding the amount of periprocedural blood loss to the
endpoint deﬁnition of VARC-2 increases the predictive
precision for impaired clinical outcomes.
During the initial TAVI experience, event reporting was
inconsistent and complication rates were not comparable
between trials and large, real-world patients registries owing
to the lack of standardized endpoint deﬁnitions. In 2011,
VARC addressed this unmet scientiﬁc need and provided a
consensus document with expert recommendations for a
uniﬁed endpoint assessment after TAVI.12 VARC endpoint
deﬁnitions have been rapidly adopted in the scientiﬁc
community and currently serve as a reproducible and
Table 3. Location and Severity of All Bleeding Events According to VARC-2
Overt Bleeding Complications
In-Hospital Bleeding Complications
Total
N=152
Life-Threatening
N=65
Major
N=52
Minor
N=35
PRBC Transfusion
(MeanSD)
Access site, n (%) 101 (66.4) 38 (58.5) 44 (84.6) 19 (54.3) 2.03.3
Gastrointestinal, n (%) 10 (6.6) 5 (7.7) 0 (0.0) 5 (14.3) 1.81.8
Pulmonary, n (%) 4 (2.6) 2 (3.1) 1 (1.9) 1 (2.9) 2.01.0
Intracranial, n (%) 3 (2.0) 3 (4.6) 0 (0.0) 0 (0.0) 1.72.1
Intraocular, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Retroperitoneal, n (%) 5 (3.3) 4 (6.2) 1 (1.9) 0 (0.0) 4.42.1
Genitourinary, n (%) 6 (3.9) 2 (3.1) 2 (3.8) 2 (5.7) 1.32.0
Pericardial, n (%) 8 (5.3) 8 (12.3) 0 (0.0) 0 (0.0) 5.04.5
Other, n (%) 12 (7.9) 3 (4.6) 3 (5.8) 6 (17.1) 2.13.0
Epistaxis, n (%) 3 (2.0) 0 (0.0) 1 (1.9) 2 (5.7) 00.0
Periprocedural blood loss, n (%) 120 (44.1) 24 (27.0) 71 (57.7) 25 (41.7) 1.51.5
Depicted are counts (%). PRBC indicates packed red blood cell; VARC, Valve Academic Research Consortium.
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standardized tool to compare hemodynamic and clinical
results post-TAVI in routine clinical practice.
Bleeding complications are among the most frequent
adverse events post-TAVI and are observed in every fourth
patient with relevant differences in severity. Two thirds of
bleeding events are attributed to the access site and are
considered vascular- or access-related complications, which
are independently associated with impaired clinical outcomes
and responsible for a substantial increase in healthcare
costs.6 At this point in time, current efforts in device
iterations are mainly focused on the reduction of device-
related and, speciﬁcally, access-related vascular complica-
tions with the development of novel TAVI delivery catheters
and prostheses with a smaller and less-traumatic proﬁle and
surface.
Recently, Genereux and coworkers draw attention to late
bleeding events after hospital discharge.18 With an analysis
on the incidence, predictors, and the prognostic impact of
late bleeding complications post-TAVI in the PARTNER
patient population, these investigators observed a strong
and independent association of late bleeding and mortality
after 12 months of follow-up (HRadj, 3.91; 95% CI, 2.67 to
5.71; P<0.001). Owing to the age and risk of the patient
population included into the PARTNER trial, it was not
surprising that gastrointestinal (40.8%) and neurological
(15.5%) complications were among the most frequent late
bleeding complications beyond 30 days of follow-up. Given
that these bleeding events have been mainly attributed to
the patients’ bleeding susceptibility, the postoperative
antiplatelet and -thrombotic management played a
Table 4. In-Hospital Bleeding and Mortality According to Various Bleeding Deﬁnitions
Bleeding Deﬁnition Criteria Stratiﬁcation
No. of Patients
N=489
Mortality
In-Hospital
N=16
30 Days
N=28
1-Year
N=82
No bleeding 239 2 (0.8) 5 (2.1) 28 (14.2)
In-hospital bleeding 130 9 (6.9) 14 (10.8) 26 (23.4)
Periprocedural blood loss 120 5 (4.2) 9 (7.5) 28 (25.2)
VARC-2
VARC 2 (life-threatening) 60 8 (13.3) 10 (16.7) 16 (30.0)
VARC 2 (major) 49 1 (2.0) 4 (8.2) 9 (20.2)
VARC 2 (minor) 21 0 (0.0) 0 (0.0) 1 (7.7)
BARC
BARC 5b 2 2 (100.0) 2 (0.0) 2 (0.0)
BARC 3c 1 0 (0.0) 1 (27.0) 1 (27.0)
BARC 3b 57 6 (10.5) 7 (12.3) 13 (26.3)
BARC 3a 48 1 (2.1) 4 (8.3) 9 (20.7)
BARC 2 22 0 (0.0) 0 (0.0) 1 (7.1)
TIMI
TIMI (major) 56 8 (14.3) 9 (16.1) 15 (30.2)
TIMI (minor) 51 1 (2.0) 5 (9.8) 10 (21.6)
TIMI (minimal) 23 0 (0.0) 0 (0.0) 1 (6.7)
GUSTO
GUSTO (severe or life-threatening) 18 6 (33.3) 7 (38.9) 8 (46.5)
GUSTO (moderate) 63 3 (4.8) 5 (7.9) 12 (22.1)
GUSTO (mild) 49 0 (0.0) 2 (4.2) 6 (16.5)
Modified VARC
Modified VARC (life-threatening) 84 13 (15.5) 15 (17.9) 27 (35.8)
Modified VARC (major) 120 1 (0.8) 7 (5.8) 19 (17.5)
Modified VARC (minor) 46 0 (0.0) 1 (2.2) 8 (23.5)
Depicted are counts (cases over total for in-hospital mortality and Kaplan–Meier incidence rates for 30 days and 1-year mortality in %). BARC indicates Bleeding Academic Research
Consortium; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries investigators; TIMI, Thrombolysis in Myocardial Infarction
investigators; VARC, Valve Academic Research Consortium.
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substantial role in this frail and vulnerable patient
population. The results of currently ongoing studies
(NCT01559298; NCT02247128; and NCT02224066) will
soon inform the discussion on optimal medical therapy
and the best antiplatelet strategy after a successful TAVI
procedure.
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Figure 1. Landmark analysis showing the risk of mortality at 30 days and from 30 days to 12 months of follow-up in patients with
symptomatic, severe aortic stenosis undergoing TAVI. Bleeding complications have been adjudicated according to the deﬁnition of VARC-2,
BARC, TIMI, GUSTO, and the modiﬁed VARC. Cumulative event curves are presented for patients with (red curve) and without bleeding event
(blue curve) according to the deﬁnition of VARC-2 (life-threatening bleeding—A), of BARC (bleeding category ≥3—B), TIMI (major bleeding—C),
GUSTO (severe or life-threatening bleeding—D), and modiﬁed VARC (life-threatening bleeding—E). BARC indicates Bleeding Academic Research
Consortium; CI, conﬁdence interval; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries investigators; HR, hazard ratio; TAVI, transcatheter aortic valve implantation; TIMI, Thrombolysis in Myocardial Infarction investigators;
VARC, Valve Academic Research Consortium.
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Bleeding complications post-TAVI are independently asso-
ciated with worse clinical outcomes as reﬂected by a
substantial increase in mortality at 30 days and 12 months
after the intervention, a ﬁnding that is consistent with the
results of previous studies investigating the impact of
bleeding complications in a TAVI patient population.5,7,19,20
It remains noteworthy that the deleterious effect of in-hospital
bleeding is only present within the ﬁrst 30 days with no
additional hazard arising between 30 days and 12 months
after TAVI, as shown in our landmark analysis (Figure 1). This
observation among TAVI patients differs from that in patients
undergoing percutaneous coronary intervention (PCI), where a
continuous and progressive risk of mortality is still apparent
between 30 days and 12 months after the intervention.21 The
reasons for this observation have not been evaluated so far,
and an explanation might only be found in the inherent risk of
the available confounders of a typical elderly TAVI patient
population diluting the deleterious effect of periprocedural,
in-hospital bleeding after 30 days of follow-up.
To the best of our knowledge, the present study is the ﬁrst
to validate bleeding as part of the updated VARC-2 deﬁnitions
in a large, consecutive patient population undergoing TAVI
and comparing the predictive power of the VARC-2 deﬁnition
to already validated and accepted bleeding deﬁnitions of
BARC, TIMI, and GUSTO in other settings. In this TAVI patient
population, we found a strong association and a gradually
increased risk between the severity of VARC-2 bleeding
events and mortality. The bleeding criteria and the severity
stratiﬁed into VARC-2 minor, major, and life-threatening
bleeding complications has been proven sensitive enough to
identify and capture clinically relevant bleeding events and
show a progressive increase in mortality at short- and long-
term follow-up. Furthermore, the prognostic information and
the performance of the updated VARC-2 bleeding deﬁnition in
a TAVI patient population were comparable to the established
bleeding deﬁnitions of BARC, TIMI, and GUSTO with similar
rates of sensitivity and accuracy.
Alongside with the existing predictive power of the VARC-2
bleeding deﬁnitions for mortality, we were able to increase the
sensitivity of the preexisting deﬁnition while maintaining the
high rates of speciﬁcity and accuracy by creating a modiﬁed
version of the VARC endpoint deﬁnitions. Whereas VARC-2
explicitly mentions to capture only events of overt bleeding,
we additionally estimated the periprocedural blood loss owing
to procedural manipulation according to the preexisting
deﬁnition, and by adding these events we provided a modiﬁed
VARC deﬁnition. Life-threatening bleeding according to the
modiﬁed VARC deﬁnition was associated with a relevant
6-fold increased risk of mortality at 30 days (HR, 6.1; 95% CI,
2.9 to 12.9) and an almost 3-fold increased risk at 12 months
of follow-up (HR, 2.9; 95% CI, 1.8 to 4.6). Of note, we found a
continuous and progressive risk of mortality with a statistical
trend between 30 days and 12 months (HR, 1.77; 95% CI,
0.93 to 3.37; Figure 1), which is similar to what has been
observed in PCI populations.
Limitations
Several limitations need to be acknowledged, when interpret-
ing the results of this study. First, the study population is
based on the experience of a single, tertiary care center, and
the results may not be applicable to other centers with
different procedural experience as well as device and patient
selection. Second, owing to the sample size of the present
study and the respective event rates among patients with
bleeding complications at 30-day follow-up, this could have
Table 6. Predictivity of the Multivariable Models Without and After Inclusion of Bleeding
Multivariable Model
30-Day Mortality
P Value* C-Statistic [95% CI]
Baseline model without bleeding† — 0.744 [0.671 to 0.818]
After inclusion of VARC-2 LT bleeding <0.001 0.773 [0.706 to 0.839]
After inclusion of bleeding defined as BARC ≥3 0.002 0.776 [0.694 to 0.857]
After inclusion of bleeding defined as BARC ≥2 0.011 0.762 [0.682 to 0.842]
After inclusion of TIMI major 0.001 0.768 [0.692 to 0.844]
After inclusion of TIMI major+minor bleeding 0.002 0.776 [0.701 to 0.852]
After inclusion of GUSTO severe or LT bleeding <0.001 0.791 [0.714 to 0.869]
After inclusion of GUSTO severe or LT and moderate bleeding 0.002 0.771 [0.692 to 0.851]
After inclusion of modified VARC LT bleeding <0.001 0.814 [0.759 to 0.870]
BARC indicates Bleeding Academic Research Consortium; BMI, body mass index; CI, conﬁdence interval; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for
Occluded Coronary Arteries investigators; LT, life-threatening; TIMI, Thrombolysis in Myocardial Infarction investigators; VARC, Valve Academic Research Consortium.
*The P value is obtained from a likelihood ratio test comparing the baseline model without bleeding vs multivariable model including bleeding.
†
The baseline model includes age, sex, BMI, previous stroke, chronic obstructive pulmonary disease, and atrial ﬁbrillation at baseline.
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particular impact on the results when comparing the different
classiﬁcations of bleeding. Third, although details on bleeding
complications have been prospectively collected, we are not
able to exclude some heterogeneity and bias during the
adjudication process according to the endpoint deﬁnitions of
VARC, BARC, TIMI, and GUSTO. And, ﬁnally, although blood
sample assessment was standardized for all patients on the
morning of the intervention and daily thereafter until hospital
discharge, a certain dilutional effect of periprocedural ﬂuid
management might be depicted in the analysis on periproce-
dural blood loss.
Conclusion
Bleeding complications post-TAVI are frequent and indepen-
dently associated with impaired clinical outcomes at
short- and long-term follow-up. The current VARC-2 bleeding
deﬁnition offers a balanced severity stratiﬁcation that is
associated with a gradual increase in mortality and prognostic
information that is comparable to established bleeding
deﬁnitions (BARC, TIMI, and GUSTO). Adding the information
of periprocedural blood loss to the preexisting deﬁnition of
VARC-2 may further increase the sensitivity and predictive
power of this classiﬁcation.Ta
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Figure 2. Adjusted receiver operating characteristic curves
showing the predictive ability of bleeding according to VARC,
BARC, TIMI, GUSTO, and the modiﬁed VARC bleeding deﬁnition
criteria for mortality at 30-day follow-up. BARC indicates Bleeding
Academic Research Consortium; GUSTO, Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries investigators; LT, life-threatening; TIMI, Throm-
bolysis in Myocardial Infarction investigators; VARC, Valve
Academic Research Consortium.
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